scholarly journals The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer

2019 ◽  
Vol 7 (21) ◽  
pp. 3716-3720
Author(s):  
Indri Windarti ◽  
Wirsma Arif Harahap ◽  
Ricvan Dana Nindrea ◽  
Eti Yerizel ◽  
Primaria Dewi Rustamadji
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Random Effect ◽  
Prognostic Significance ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Phosphatase And Tensin Homolog ◽  
Pten Loss ◽  
Tensin Homolog

AIM: This study aims to determine the prognostic significance of phosphatase and tensin homolog (PTEN) loss in breast cancer. METHODS: We conducted a meta-analysis study. Sample of this study were research articles that evaluated PTEN loss and prognosis in breast cancer patients. We searched for relevant studies published in PubMed and Proquest from January 2010 to July 2018. We reviewed studies that examined the association between immunohistochemical expression of PTEN and breast cancer prognosis using meta-analysis methods. Pooled risk ratios (RR) were calculated using fixed and random-effect models. Data were processed using Review Manager 5.3 (RevMan 5.3). RESULTS: There were 7 studies conducted a systematic review then continued to evaluate the association of PTEN loss and breast cancer prognosis by meta-analysis. There was a significant association of PTEN loss with poor prognosis of breast cancer (RR = 0.76 [95% CI 0.59-0.98 p <0.07), and there was not any significant publication bias for studies included. CONCLUSION: This study confirmed PTEN loss is an important independent factor for breast cancer prognosis.

scholarly journals Prognostic and Clinicopathological Value of Cyclin E Expression in Breast Cancer: A Meta-Analysis

2021 ◽  
Author(s):  
Yufei Wang ◽  
Qijuan Yang ◽  
Deshou Ma ◽  
Zhijun Ma ◽  
Xiaowu Wang
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Meta Analysis ◽  
Cyclin E ◽  
Cochrane Collaboration ◽  
Clinicopathological Characteristics ◽  
Positive Lymph Node ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival

Abstract Background: Multiple studies have analyzed the correlation between Cyclin E and breast cancer prognosis, but the results are controversial. In this study, a meta-analysis was used to summarize the published reports, clarify the predictive value of Cyclin E in breast cancer, and the relationship with clinicopathological characteristics.Methods: A systematic search was retrieved in PubMed, Embase, Web of Science, Cochrane Collaboration Library on the comprehensive search strategy up to 24 August 2020. recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) was estimated using pooled hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (95% CIs) by univariate and multivariate analysis.Results: Twenty-eight eligible studies met our inclusion criteria. The present meta-analysis indicates that high cyclin E expression is independently associated with poor OS, BCSS, and RFS in female breast cancer patients by univariate and multivariate analysis. Furthermore, higher histological grades, estrogen receptor (ER)-negativity, positive lymph node metastasis, younger patients, and premenopausal status were associated with Cyclin E overexpression. Conclusions: High expression of Cyclin E is associated with poor breast cancer outcomes and relevant to multiple clinical characteristics.

scholarly journals Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Zhigang Zhang ◽  
Chao Ni ◽  
Wuzhen Chen ◽  
Ping Wu ◽  
Zhen Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis

The impact of chemokine receptor CXCR4 on breast cancer prognosis: A meta-analysis

2013 ◽  
Vol 37 (5) ◽  
pp. 725-731 ◽  
Author(s):  
Tong-peng Xu ◽  
Hua Shen ◽  
Ling-xiang Liu ◽  
Yong-qian Shu
Keyword(s):  
Breast Cancer ◽  
Chemokine Receptor ◽  
Meta Analysis ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Chemokine Receptor Cxcr4 ◽  
The Impact

scholarly journals Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer

2019 ◽  
Vol 39 (4) ◽  
Author(s):  
Wei-xian Chen ◽  
Liang-gen Yang ◽  
Ling-yun Xu ◽  
Lin Cheng ◽  
Qi Qian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Data ◽  
Bioinformatics Analysis ◽  
Prognostic Significance ◽  
Prognostic Index ◽  
Disease Free Survival ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Metastatic Relapse

Abstract Background: Ribonucleotide reductase M2 subunit (RRM2) plays vital roles in many cellular processes such as cell proliferation, invasiveness, migration, angiogenesis, senescence, and tumorigenesis. However, the prognostic significance of RRM2 gene in breast cancer remains to be investigated. Methods:RRM2 expression was initially evaluated using the Oncomine database. The relevance between RRM2 level and clinical parameters as well as survival data in breast cancer was analyzed using the Kaplan–Meier Plotter, PrognoScan, and Breast Cancer Gene-Expression Miner (bc-GenExMiner) databases. Results:RRM2 was overexpressed in different subtypes of breast cancer patients. Estrogen receptor (ER) and progesterone receptor (PR) were negatively correlated with RRM2 expression. Conversely, the Scarff–Bloom–Richardson (SBR) grade, Nottingham prognostic index (NPI), human epidermal growth factor receptor-2 (HER-2) status, nodal status, basal-like status, and triple-negative status were positively related to RRM2 level in breast cancer samples with respect to normal tissues. Patients with increased RRM2 showed worse overall survival, relapse-free survival, distant metastasis-free survival, disease-specific survival, and disease-free survival. RRM2 also exerted positive effect on metastatic relapse event. Besides, a positive correlation between RRM2 and KIF11 genes was confirmed. Conclusion: Bioinformatics analysis revealed that RRM2 might be used as a predictive biomarker for prognosis of breast cancer. Further studies are needed to more precisely elucidate the value of RRM2 in evaluating breast cancer prognosis.

Lymph node ratio and breast cancer prognosis: a meta-analysis

Breast Cancer ◽  
2013 ◽  
Vol 21 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Dechun Liu ◽  
Yanbin Chen ◽  
Miao Deng ◽  
Gangqiang Xie ◽  
Jianguang Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Ratio ◽  
Meta Analysis ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Node Ratio

Metformin May Block the Way Breast Cancer Metastasis: A Meta-analysis and Mechanism Review

2020 ◽  
Author(s):  
Ming Yang ◽  
Yueyuan Wang ◽  
Zhihao Zhang ◽  
Jingyu Peng ◽  
Xiao Xie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Retrospective Cohort ◽  
Cancer Metastasis ◽  
Meta Analysis ◽  
Random Effect ◽  
Breast Cancer Metastasis ◽  
Cochrane Library ◽  
Breast Cancer Patients

Abstract Background Metformin, which is cheap and easy to get, is a first-line anti-hyperglycemia drug. Recently, its anti-tumor effect has been revealed. Here we performed a meta-analysis to summarize previous studies and a narrative review to gather the mechanisms involved in the potential relationship. Methods We searched related articles in database of Pubmed, EMbase, Web of science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), the Wanfang and Sinomed and obtained 8 clinic trials that investigated the connection between metformin and breast cancer metastasis, containing 2 randomized controlled trials (RCTs) and 6 retrospective cohort studies. We evaluated each retrospective cohort study by Newcastle-Ottawa Scale (NOS), while RCT by Chcorane Risk of Bias tool. Pooled hazard ratios (HRs), risk ratios (RRs) and we calculated associated 95% confidence intervals (CIs) with a random-effect, generic inverse variance method. We also collected the possible mechanisms of cancer metastasis inhibition from metformin. Results A total of 8 studies containing 13919 breast cancer patients without distant metastasis before they got anticancer treatment. The result showed that adjuvant metformin in treatment of local breast cancer facilitated to suppress metastasis (HR = 0.69, 95% CI = 0.57–0.82, p < 0.0001, I2 = 0%), and the result was consistent with the subgroup of breast cancer patients with type 2 diabetes mellitus (T2DM) (HR = 0.68, 95% CI = 0.57–0.82, p < 0.0001, I2 = 0%). Conclusion The meta-analysis suggested metformin might repress the metastasis and be benefit to distant metastasis-free survival (DMFS) when added to systemic breast cancer therapy, supporting anti-tumor effects of metformin on breast cancer.

Sign in / Sign up

Export Citation Format

Share Document